efpeglenatide
Jump to navigation
Jump to search
Introduction
Not yet FDA-approved.
Indications
- diabetes mellitus with prior prior cardiovascular disease or stage 3 chronic renal function (eGFR 25-60 mL/min)
Dosage
- once weekly injection
Adverse effects
- gastrointestinal adverse effects may be severe
- constipation, diarrhea, nausea, vomiting, or bloating
Mechanism of action
- GLP-1 agonist
- renal & cardiovascular protective effects
- benefits urinary albumin/creatinine ratio more than eGFR
More general terms
References
- ↑ Gerstein HC, Sattar N, Rosenstock J et al Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 2021 Jun 28; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/34215025 https://www.nejm.org/doi/10.1056/NEJMoa2108269